Screening of a further set of 150 consecutive diagnostic samples revealed mutations in 86% of the 36 CRC specimens that could be analyzed, predominantly in KRAS (42%), TP53 (33%), APC (31%), BRAF (14%), SMAD4 (14%) and FBXW7 (11%). Here, TP53 is linked to colorectal carcinoma.